Kislinger, Thomas

Open Protocols

This person has no open protocols at the present moment.

Closed Protocols

This person has no closed protocols at the present moment.


Publication NamePubMed IDJournal
A proteomic investigation of isogenic radiation resistant prostate cancer cell lines. 34152685 Proteomics Clin Appl
Optimization of small extracellular vesicle isolation from expressed prostatic secretions in urine for in-depth proteomic analysis. 35119778 J Extracell Vesicles
Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena. 35505417 J Hematol Oncol
Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry. 34453155 Nat Rev Urol
Targeted Mass Spectrometry of a Clinically Relevant PSA Variant from Post-DRE Urines for Quantitation and Genotype Determination. 32614141 Proteomics Clin Appl
The Proteogenomic Landscape of Curable Prostate Cancer. 30889379 Cancer Cell


Technology for the detection of all proteins present in a given signal at a specific time. Our lab utilizes modern mass spectrometry-based proteomics the detect and quantify protein in clinical samples for the discovery of novel protein biomarkers.
Biomarker Discovery
A biomarker could be any molecule (or signal) that indicates the presence, aggressiveness or treatment response of a given disease. Our lab applies proteomics technologies to discover novel biomarkers for the early detection of aggressive prostate cancer.
Extracellular Vesicles
Extracellular vesicles (EVs) are lipid bilayer particles that are released by any cell in the body. Extracellular vesicles are reflective of their cell of origin and carry intracellular cargo from the cells that release them. Cargo molecules include proteins, RNA, lipids and metabolites. EVs are thought to participate in intercellular communication in numerous biological processes.
Cell Surface Proteins
Proteins that are expressed at the plasma membrane are involved in numerous important biological processes (cell-cell adhesion, interaction with the extracellular space, ligand binding, etc.). Cell surface proteins also account for over 60% of FDA approved drug targets. Due to their hydrophobic nature detection of these proteins has been traditionally challenging. Recent advances in cell surface protein capture now enable large-scale quantitation of cell surface proteomes via mass spectrometry-based proteomics. We are interested in applying cell surface capture technologies to detect novel therapeutic targets for various cancers.
Protein glycosylation patterns can change during the process of tumor development and the identification of these events may facilitate early cancer diagnosis and enhance the ability to monitor neoplastic disease progression. The identification of altered protein glycosylation patterns during tumor development may reveal tumor cell regulatory mechanisms at the molecular level.
Enables a more comprehensive understanding of molecular changes contributing to normal development, cellular response, and disease. Using multiple, complementary omics technology (DNA, RNA, protein, metabolites) in an integrative manner we aim to connect genotype to phenotype and fuel the discovery of novel drug targets and biomarkers.

To update protocols, publications, biomarkers, or science data, please contact the Data Management and Coordinating Center.